Pfizer Inc. (NYSE:PFE) partners with Olema Pharmaceuticals for a new trial on metastatic breast cancer, combining Palazestrant and Atirmociclib. Pfizer supplies Atirmociclib, while Olema leads the trial. Both companies jointly own data, but Olema retains commercial rights for Palazestrant. This is their second collaboration following a previous study with Pfizer’s palbociclib.

Pfizer Inc. (NYSE:PFE) is a global biopharmaceutical company known for discovering, developing, and marketing medicines and vaccines for various diseases. The company continues to make strides in the medical field, particularly in the fight against breast cancer with its latest trial collaboration.

Investors are exploring the potential of Pfizer Inc. (NYSE:PFE) as an investment, but some believe other AI stocks offer greater upside potential and less downside risk. For those seeking an undervalued AI stock with significant growth potential, consider exploring Insider Monkey’s free report on the best short-term AI stock.

For more insights on stocks that could double in three years or hidden AI stocks to invest in, check out Insider Monkey’s articles. Disclosure: None. This news is originally published on Insider Monkey’s platform.

Read more at Yahoo Finance: Pfizer Inc (PFE) Announces New Trial Collaboration With Olema Pharmaceuticals